|
|
|
|
|
 |
Board of Directors
|
|
| |
|
Larry W. Papasan
Larry W. Papasan has been a director and Chairman of BioMimetic's board of directors since August 2005. Mr. Papasan has been a director of Smith and Nephew, Inc. since June 2002. From July 1991 to May 2002, he served as President of Smith and Nephew Orthopaedics. Mr. Papasan has served as a member of the Board of Directors of Reaves Utility Income Fund since February 2003 and of Triumph Bank since April 2005.
|
| |
Chris Ehrlich
Chris Ehrlich has served as a member of BioMimetic's board of directors since October 2004. He is currently a Partner at InterWest Partners, a diversified venture capital firm, which he joined in August 2000. Before InterWest, Ehrlich was Director, Licensing & Business Development at Purdue Pharma, a private pharmaceutical firm based in Stamford, CT. He has also worked in business development at Genentech, Inc., in venture capital at The U.S. Russia Investment Fund, and in biotechnology strategy development at LEK Consulting. Ehrlich earned his Bachelor's degree from Dartmouth College, cum laude and an MBA from the J.L. Kellogg Graduate School of Management where he serves as an instructor and advisor to the Biotech Program. In addition to BioMimetic, he currently serves on the boards of QuatRxPharmaceuticals, Carbylan BioSurgery, Inc., KAI Pharmaceuticals, TransOral Pharmaceuticals, Inc. and Xenon Pharmaceuticals.
|
| |
Charles Federico
Charles Federico joined the BioMimetic board of directors in June of 2007. Mr. Federico currently serves as a director of Orthofix International N.V., where he also served as president from 1996 to 2001, and as president and chief executive officer from 2001 to 2006. From 1985 to 1996, Mr. Federico was general manager then president of Smith & Nephew Endoscopy (formerly Dyonics, Inc.). From 1981 to 1985, Mr. Federico served as vice president of Dyonics, initially as director of marketing and subsequently as general manager. Previously, he held management and marketing positions with General Foods Corporation, Air Products Corporation, Puritan Bennett Corporation and LSE Corporation. Mr. Federico also currently serves on the boards of SRI/Surgical Express, Inc., SaluMedica, LLC and Mako Surgical Corp.
|
| |
Gary Friedlaender, M.D.
Dr. Gary Friedlaender has been a director of BioMimetic's board of directors since September 2006. Dr. Friedlaender is Chief of the Department of Orthopaedics and Rehabilitation at Yale New Haven Hospital and Professor of Orthopaedics and Rehabilitation at the Yale University School of Medicine. After earning his medical degree at the University of Michigan Medical School in Ann Arbor, Dr. Friedlaender completed his general surgery internship and residency at the University of Michigan Medical Center, and his orthopaedic residency at the Yale – New Haven Hospital and Newington Children's Hospital in Newington, Conn. He then completed a fellowship in musculoskeletal oncology at Massachusetts General Hospital in Boston. During active duty in the U.S. Navy, he was Director of the Naval Medical Research Institute's Tissue Bank Division in Bethesda, Md., and has since served on various medical advisory committees for the National Institutes of Health. Dr. Friedlaender has received several research grants and written numerous articles related to orthopedic reconstruction and bone grafting.
|
| |
Sam Lynch, D.M.D., D.M.Sc.
Samuel E. Lynch, D.M.D., D.M.Sc. is a founder of BioMimetic and has served as President, Chief Executive Officer and a director since its inception. Dr. Lynch served as Chairman of BioMimetic's board of directors from inception until August 2005. Prior to founding BioMimetic, Dr. Lynch spent over four years at Luitpold Pharmaceuticals, Inc., a US subsidiary of Sankyo, Co., Ltd. as Vice President with P&L responsibility for the Osteohealth Co., a division focused on bone and tissue regeneration. Dr. Lynch successfully managed all aspects of the business, including sales, marketing, clinical development and G&A functions, resulting in a "turn-around" and conversion into a highly profitable business. Prior to joining Sankyo – Luitpold, Dr. Lynch was the Executive Director for Research and Development for the Institute of Molecular Biology, a private research institute affiliated with Harvard University, where he directed research in bone and tissue healing. He concurrently served on the faculty at Harvard School of Dental Medicine for six years, from which he earlier received a Certificate of Specialty in Periodontology. Dr. Lynch also received a Doctorate of Medical Sciences from the Harvard Medical School. In addition to his industry success, Dr. Lynch has a long record of scientific accomplishments, has published and lectured extensively and is a co-inventor of BioMimetic's technologies.
|
| |
Jim Murphy
Jim Murphy has been a director since September 2005. Mr. Murphy has served as Senior Vice President, Finance and Administration, and as Chief Financial Officer, of Immunicon Corporation since September 2000. From April 1999 to September 2000, Mr. Murphy served as Immunicon's Vice President, Finance and Administration. From April 1998 to April 1999, he was a consultant providing financial services to various venture-backed health care companies. From March 1996 to April 1998, Mr. Murphy was Vice President, Finance and Administration, and Chief Financial Officer of Apollon, Inc., a biotechnology company engaged in the development of DNA-based vaccines. From 1988 to 1995 Mr. Murphy served as Vice President, Chief Financial Officer and as a director of Infopage, Inc., a publicly-held radio beeper company that operated throughout the US. From 1987 to 1988, Mr. Murphy was Corporate Controller and Treasurer of American Cellular Network Corporation, a publicly-traded company that operated cellular telephone systems in New Jersey and Delaware. He holds a B.S. in Accounting, cum laude, from Villanova University, and is a certified public accountant.
|
| |
Doug Watson
Doug Watson has been a director since BioMimetic's inception. Mr. Watson's career spanned 33 years with Geigy/Ciba-Geigy/Novartis, in a variety of positions in the UK, Switzerland and the US. From 1986 to 1996, he was President of Ciba Pharmaceuticals Division and was appointed President and Chief Executive Officer of Ciba-Geigy Corporation in 1996. Mr. Watson became President and Chief Executive Officer of Novartis Corporation in 1997 when the merger of Ciba-Geigy and Sandoz was approved by the FTC. In May 1999, Mr. Watson elected to take early retirement from Novartis. That same year he founded Pittencrieff Glen Associates, a private management consulting company. In addition to BioMimetic, he has served as the chairman of OraSure Technologies Inc. since March 2003 and as a director since April 2002. He has served as the chairman of Innovative Drug Delivery Systems Inc. since June 2003 and as a director since March 2001. He currently serves as a director on the boards of Engelhard Corporation since 1991, Dendreon Corporation since March 2000, Genta Inc. since April 2002, BioElectronics Inc. since November 2002 and InforMedix Inc. since March 2002. From July 2000 to September 2001, he also served as a member of the Board and acting Chief Executive Officer of ValiGen N.V. He is also a member of the President's Advisory Board of Drew University. Mr. Watson holds an M.A. degree in pure mathematics from Churchill College, Cambridge University, and is a member of the Chartered Institute of Management Accountants.
|
| |
|
|
| |
 |
|
|
| |
| |
|
|
|
|
|
|
